abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Cette page n’est pas disponible en Français et est affichée en English

Réponse de l'entreprise

23 Nov 2015

Auteur:
Novo Nordisk

Novo Nordisk statement

We support a mandatory reporting mechanism for European companies that manufacture or contract to manufacture products containing 3TG necessary to product functionality or manufacture.  The reporting mechanism should mirror the US Securities and Exchange Commission requirements to ensure a consistent international framework.